Abstract
In this issue of Blood, Nervi and colleagues and Zeng and colleagues independently report similar findings in both in vitro and in vivo AML models, showing chemosensitization by blocking CXCR4/CXCL12 (SDF-1α:stromal cell-derived factor 1) signaling using novel CXCR4 antagonist bicyclams, namely AMD3100 (plerixafor) and AMD3465.
| Original language | English |
|---|---|
| Pages (from-to) | 6045-6046 |
| Number of pages | 2 |
| Journal | Blood |
| Volume | 113 |
| Issue number | 24 |
| DOIs |
|
| State | Published - 2009 |